NASDAQ:DRNADicerna Pharmaceuticals Stock Price, Forecast & News

Dicerna Pharmaceuticals' stock was trading at $16.88 on March 11th, 2020 when COVID-19 reached pandemic status according to the World Health Organization (WHO). Since then, DRNA shares have increased by 24.6% and is now trading at $21.03.
View which stocks have been most impacted by Coronavirus.

11 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Dicerna Pharmaceuticals in the last year. There are currently 11 buy ratings for the stock, resulting in a consensus recommendation of "Buy."
View analyst ratings for Dicerna Pharmaceuticals.

Dicerna Pharmaceuticals is scheduled to release its next quarterly earnings announcement on Thursday, November 5th 2020.
View our earnings forecast for Dicerna Pharmaceuticals.

Dicerna Pharmaceuticals Inc (NASDAQ:DRNA) posted its quarterly earnings results on Thursday, August, 6th. The biopharmaceutical company reported ($0.43) EPS for the quarter, missing analysts' consensus estimates of $0.11 by $0.54. Dicerna Pharmaceuticals had a negative net margin of 213.04% and a negative return on equity of 74.79%.
View Dicerna Pharmaceuticals' earnings history.

11 equities research analysts have issued twelve-month target prices for Dicerna Pharmaceuticals' shares. Their forecasts range from $25.00 to $50.00. On average, they anticipate Dicerna Pharmaceuticals' stock price to reach $35.30 in the next year. This suggests a possible upside of 67.9% from the stock's current price.
View analysts' price targets for Dicerna Pharmaceuticals.

Media stories about DRNA stock have trended very positive recently, InfoTrie reports. The research firm scores the sentiment of media coverage by analyzing more than six thousand blog and news sources. The firm ranks coverage of publicly-traded companies on a scale of negative five to five, with scores closest to five being the most favorable. Dicerna Pharmaceuticals earned a daily sentiment score of 4.0 on InfoTrie's scale. They also assigned press coverage about the biopharmaceutical company a news buzz of 0.0 out of 10, meaning that recent media coverage is extremely unlikely to have an effect on the company's share price in the next several days.
View the latest news about Dicerna Pharmaceuticals.

Dicerna Pharmaceuticals saw a decrease in short interest in June. As of June 30th, there was short interest totaling 2,960,000 shares, a decrease of 7.8% from the June 15th total of 3,210,000 shares. Based on an average daily volume of 639,600 shares, the days-to-cover ratio is presently 4.6 days. Currently, 4.6% of the shares of the company are short sold.
View Dicerna Pharmaceuticals' Current Options Chain.

Some companies that are related to Dicerna Pharmaceuticals include Mirati Therapeutics (MRTX), Myokardia (MYOK), Ultragenyx Pharmaceutical (RARE), Reata Pharmaceuticals (RETA), United Therapeutics (UTHR), Zai Lab (ZLAB), Schrodinger (SDGR), Legend Biotech (LEGN), HUTCHISON CHINA/S (HCM), Arrowhead Pharmaceuticals (ARWR), HYPERA S A/S (HYPMY), Evotec (EVTCY), Blueprint Medicines (BPMC), FibroGen (FGEN) and Amicus Therapeutics (FOLD).
View all competitors.

Based on aggregate information from My MarketBeat watchlists, some companies that other Dicerna Pharmaceuticals investors own include Axsome Therapeutics (AXSM), Amarin (AMRN), Strongbridge Biopharma (SBBP), Arbutus Biopharma (ABUS), TG Therapeutics (TGTX), Crispr Therapeutics (CRSP), Gilead Sciences (GILD), Exelixis (EXEL), ImmunoGen (IMGN) and Array Biopharma (ARRY).

Dicerna Pharmaceuticals trades on the NASDAQ under the ticker symbol "DRNA."

Dicerna Pharmaceuticals' stock is owned by a number of retail and institutional investors. Top institutional investors include UBS Group AG (1.83%), Candriam Luxembourg S.C.A. (1.82%), Emerald Advisers LLC (0.70%), Emerald Mutual Fund Advisers Trust (0.47%), Swiss National Bank (0.19%) and Alps Advisors Inc. (0.14%). Company insiders that own Dicerna Pharmaceuticals stock include Adam Koppel, Bain Capital Life Sciences Inv, Bob D Brown, Brian K Halak, Dennis Langer, Douglas Fambrough, James B Weissman, John B Green and Peter Kolchinsky.
View institutional ownership trends for Dicerna Pharmaceuticals.

DRNA stock was sold by a variety of institutional investors in the last quarter, including UBS Group AG, Emerald Advisers LLC, Emerald Mutual Fund Advisers Trust, Cadence Capital Management LLC, First Trust Advisors LP, Alps Advisors Inc., WINTON GROUP Ltd, and Hancock Whitney Corp. Company insiders that have sold Dicerna Pharmaceuticals company stock in the last year include Adam Koppel, Bain Capital Life Sciences Inv, Bob D Brown, Douglas Fambrough, James B Weissman, John B Green, and Peter Kolchinsky.
View insider buying and selling activity for Dicerna Pharmaceuticals.

DRNA stock was purchased by a variety of institutional investors in the last quarter, including Candriam Luxembourg S.C.A., Russell Investments Group Ltd., Swiss National Bank, Rafferty Asset Management LLC, Jennison Associates LLC, Trexquant Investment LP, Principal Financial Group Inc., and Moody Aldrich Partners LLC.
View insider buying and selling activity for Dicerna Pharmaceuticals.

Shares of DRNA can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

One share of DRNA stock can currently be purchased for approximately $21.03.

Dicerna Pharmaceuticals has a market capitalization of $1.55 billion and generates $23.90 million in revenue each year. The biopharmaceutical company earns $-120,460,000.00 in net income (profit) each year or ($1.76) on an earnings per share basis. Dicerna Pharmaceuticals employs 78 workers across the globe.

The official website for Dicerna Pharmaceuticals is www.dicerna.com.

Dicerna Pharmaceuticals' mailing address is 33 HAYDEN AVENUE, LEXINGTON MA, 02421. The biopharmaceutical company can be reached via phone at 617-621-8097 or via email at [email protected]